
Tarsons Products (TARSONS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
913.6M
Gross Profit
620.6M
67.93%
Operating Income
47.7M
5.22%
Net Income
17.8M
1.95%
EPS (Diluted)
₹0.34
Balance Sheet Metrics
Total Assets
10.8B
Total Liabilities
4.5B
Shareholders Equity
6.3B
Debt to Equity
0.71
Cash Flow Metrics
Operating Cash Flow
100.0M
Free Cash Flow
-231.3M
Revenue & Profitability Trend
Tarsons Products Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 3.9B | 2.9B | 2.8B | 3.0B | 2.3B |
Cost of Goods Sold | 1.3B | 942.9M | 782.4M | 800.6M | 742.8M |
Gross Profit | 2.6B | 2.0B | 2.0B | 2.2B | 1.5B |
Gross Margin % | 67.0% | 68.0% | 72.2% | 73.2% | 67.4% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 219.6M | 137.5M | 105.0M | 82.0M |
Other Operating Expenses | 868.6M | 349.0M | 267.2M | 257.4M | 183.8M |
Total Operating Expenses | 868.6M | 568.6M | 404.8M | 362.4M | 265.8M |
Operating Income | 482.3M | 633.5M | 1.0B | 1.3B | 923.8M |
Operating Margin % | 12.3% | 21.5% | 37.1% | 44.8% | 40.5% |
Non-Operating Items | |||||
Interest Income | - | 17.8M | 28.9M | 13.1M | 2.9M |
Interest Expense | 193.9M | 100.2M | 43.9M | 39.8M | 27.2M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 448.0M | 607.7M | 1.1B | 1.3B | 924.3M |
Income Tax | 150.3M | 181.3M | 280.1M | 343.2M | 235.6M |
Effective Tax Rate % | 33.6% | 29.8% | 25.8% | 25.4% | 25.5% |
Net Income | 297.7M | 426.4M | 807.1M | 1.0B | 688.7M |
Net Margin % | 7.6% | 14.5% | 28.7% | 33.6% | 30.2% |
Key Metrics | |||||
EBITDA | 1.3B | 1.1B | 1.4B | 1.6B | 1.1B |
EPS (Basic) | ₹5.60 | ₹8.01 | ₹15.17 | ₹19.46 | ₹13.52 |
EPS (Diluted) | ₹5.60 | ₹8.01 | ₹15.17 | ₹19.46 | ₹13.52 |
Basic Shares Outstanding | 53160714 | 53210000 | 53210000 | 51740000 | 50940000 |
Diluted Shares Outstanding | 53160714 | 53210000 | 53210000 | 51740000 | 50940000 |
Income Statement Trend
Tarsons Products Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 251.3M | 171.1M | 590.6M | 774.4M | 23.3M |
Short-term Investments | 6.2M | 55.0M | 9.6M | 84.4M | - |
Accounts Receivable | 796.2M | 778.9M | 658.0M | 651.8M | 470.4M |
Inventory | 1.3B | 1.3B | 1.1B | 823.7M | 467.0M |
Other Current Assets | 111.6M | 60.2M | 118.5M | 111.0M | - |
Total Current Assets | 2.4B | 2.4B | 2.5B | 2.4B | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 4.7B | 1.5B | 1.1B | 924.4M | 587.9M |
Goodwill | 967.9M | 1.0B | 5.1M | 6.6M | 5.8M |
Intangible Assets | 317.4M | 366.0M | 5.1M | 6.6M | 5.8M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 604.8M | 1.3B | 1.2B | -1.0M | -530.0K |
Total Non-Current Assets | 8.4B | 7.4B | 4.7B | 3.0B | 1.8B |
Total Assets | 10.8B | 9.7B | 7.3B | 5.4B | 3.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 157.1M | 146.4M | 96.5M | 129.5M | 59.8M |
Short-term Debt | 1.3B | 1.6B | 299.5M | 122.8M | 301.8M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 72.1M | 40.4M | 38.9M | 46.8M | 10.0K |
Total Current Liabilities | 1.8B | 2.1B | 629.2M | 349.1M | 418.0M |
Non-Current Liabilities | |||||
Long-term Debt | 2.1B | 1.1B | 807.4M | 93.9M | 33.2M |
Deferred Tax Liabilities | 93.9M | 92.2M | 54.1M | 43.6M | 32.8M |
Other Non-Current Liabilities | 520.0M | 245.2M | 72.8M | 1.0M | 530.0K |
Total Non-Current Liabilities | 2.7B | 1.5B | 934.6M | 194.8M | 98.1M |
Total Liabilities | 4.5B | 3.6B | 1.6B | 544.0M | 516.1M |
Equity | |||||
Common Stock | 106.4M | 106.4M | 106.4M | 106.4M | 1.9M |
Retained Earnings | - | 4.5B | 4.1B | 3.3B | 2.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 6.3B | 6.1B | 5.7B | 4.9B | 2.4B |
Key Metrics | |||||
Total Debt | 3.4B | 2.7B | 1.1B | 216.6M | 335.0M |
Working Capital | 668.5M | 221.2M | 1.9B | 2.1B | 710.0M |
Balance Sheet Composition
Tarsons Products Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 448.0M | 607.7M | 1.1B | 1.3B | 924.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -34.1M | 93.4M | -320.7M | -480.1M | -163.3M |
Operating Cash Flow | 571.9M | 767.0M | 769.5M | 890.9M | 783.4M |
Investing Activities | |||||
Capital Expenditures | -1.5B | -1.8B | -1.9B | -1.3B | -641.6M |
Acquisitions | 0 | -651.4M | - | - | - |
Investment Purchases | -835.0M | -49.0M | 0 | -1.8B | -626.9M |
Investment Sales | 875.6M | 4.2M | 69.9M | 1.7B | 626.9M |
Investing Cash Flow | -1.5B | -2.5B | -1.8B | -1.4B | -641.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | 0 | -220.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 1.6B | 855.3M | 1.1B | 433.2M | 65.2M |
Debt Repayment | -14.9B | -827.6M | -249.8M | -2.9B | -1.5B |
Financing Cash Flow | -13.7B | 1.0B | 791.9M | -1.2B | -1.6B |
Free Cash Flow | -374.7M | -816.3M | -1.1B | -485.0M | 38.3M |
Net Change in Cash | -14.6B | -719.8M | -257.8M | -1.7B | -1.5B |
Cash Flow Trend
Tarsons Products Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
63.57
Forward P/E
26.61
Price to Book
2.78
Price to Sales
4.40
PEG Ratio
-1.16
Profitability Ratios
Profit Margin
6.90%
Operating Margin
5.22%
Return on Equity
4.72%
Return on Assets
2.76%
Financial Health
Current Ratio
1.38
Debt to Equity
53.82
Beta
0.11
Per Share Data
EPS (TTM)
₹5.19
Book Value per Share
₹118.59
Revenue per Share
₹75.44
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
tarsons | 17.6B | 63.57 | 2.78 | 4.72% | 6.90% | 53.82 |
Poly Medicure | 192.9B | 53.60 | 7.09 | 12.24% | 21.18% | 6.52 |
Dr Agarwal's Health | 144.1B | 358.78 | 7.71 | 1.14% | 5.66% | 49.87 |
Laxmi Dental | 19.2B | 81.72 | 9.07 | 15.22% | 9.53% | 9.35 |
Prevest Denpro | 6.4B | 35.41 | 6.08 | 17.20% | 28.73% | 0.00 |
Centennial Surgical | 576.2M | 2,482.50 | 1.87 | -4.76% | -3.42% | 108.97 |
Financial data is updated regularly. All figures are in the company's reporting currency.